Detalhe da pesquisa
1.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Clin Infect Dis
; 78(4): 870-879, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37967326
2.
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Emerg Infect Dis
; 28(3): 734-738, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35202536
3.
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
Drugs R D
; 24(1): 1-12, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494581
4.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine
; 91: 104562, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099841
5.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Lancet Infect Dis
; 22(1): 110-122, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529962
6.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Lancet Infect Dis
; 22(1): 97-109, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529963